Neuralink gets breakthrough tag for sight-restoring implant

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that promises to restore the sight of people with vision impairment.

Elon Musk’s Neuralink brain interface chip set for human tri...

Clinical trials of a wireless brain chip developed by Elon Musk’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

Longer-term data raise prospects for Apellis' pegcetacoplan

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from

Apellis reports mixed data with eye drug, but plans to file ...

Apellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major cause of blindness – with one hit and one miss in its phase 3 programme.

First patient dosed in trial of Allergan/Editas’ CRISPR blin...